OncoSec Provides Leadership Update

Aug 16, 2021 4:01pm EDT

OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

Jul 26, 2021 8:30am EDT

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

Jul 06, 2021 4:01pm EDT

OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

Jun 24, 2021 4:30pm EDT

OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

Jun 14, 2021 8:30am EDT

OncoSec to Present at the Raymond James Human Health Innovation Conference

May 27, 2021 8:30am EDT

OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management

May 17, 2021 8:30am EDT

OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma

Apr 15, 2021 8:30am EDT

OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors

Apr 14, 2021 8:30am EDT

OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Mar 25, 2021 8:39am EDT